Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Filings
41 filings of COHANCE since November 2024; the newest 40 below.
transcript 11, presentation 11, board outcome 9, credit rating 6, results 4
| Filed | Type | Subject | |
|---|---|---|---|
| 11 Nov 2026 | transcript Capex, Guidance, Legal, Results | Cohance Lifesciences Limited has informed the Exchange about TranscriptAI summaryCohance Lifesciences filed the transcript of its Q2 FY27 earnings conference call held on 6 November 2026, covering results for the quarter and half year ended 30 September 2026. Management said Q2 revenue rose 13% sequentially to INR 4,767 million and adjusted EBITDA rose to INR 458 million from INR 92 million in Q1, with adjusted EBITDA margin at about 10%. Management expects H2 FY27 to show year-on-year growth in both revenue and EBITDA, while Specialty Chemicals revenue is now expected to decline year-on-year in FY27. Management said Pharma CDMO revenue was 27% lower year-on-year in Q2 and 32% lower in H1, and that API+ Q2 revenue was INR 2,671 million, up 5% year-on-year. Management reported H1 capital expenditure of a little over INR 1 billion and cash and liquid investments of about INR 2.9 billion against borrowings of about INR 2.3 billion at end-September. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Nov 2026 | presentation Capex, Guidance, Results | Cohance Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryRevised Investor Presentation for Q2 and H1 FY27, replacing the version submitted on 6 November 2026, with corrections and alignments for consistency and clarity. Q2FY27 revenue from operations was INR 4,767 Mn, down 14.2% YoY and up 12.9% QoQ; adjusted EBITDA was INR 458 Mn (9.6% margin) versus 2.2% in Q1FY27. Q2FY27 reported PAT was INR 152 Mn; adjusted PAT was INR 75 Mn, returning to positive territory; gross margin was 70.8%, down 378 bps YoY. Management said Pharma CDMO revenue fell 27.4% YoY in Q2 and 32.7% in H1, and expects H2FY27 revenue and EBITDA to grow YoY and to be stronger than H1. Management reported H1FY27 free cash flow of INR 885 Mn, cash on books of INR 2,943 Mn and capex of INR 1,080 Mn. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Nov 2026 | presentation Capex, Guidance, Results | Cohance Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryInvestor presentation on unaudited financial results for the quarter and half year ended 30 September 2026 (Q2 FY2027). Q2 FY27 consolidated revenue from operations was INR 4,766 Mn, up 12.9% QoQ but down 14.2% YoY; adjusted EBITDA was INR 459 Mn with a 9.6% margin; adjusted profit after tax was INR 74 Mn. Gross margin was 70.8%, down 377 basis points YoY; free cash flow was INR 1,338 Mn in the quarter and cash on books was INR 2,943 Mn. Management said H2 FY27 revenue and EBITDA are expected to grow YoY, with H2 stronger than H1. Management said it plans to announce capex towards capabilities in adjacencies and R&D for the One Cohance platform. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Nov 2026 | board outcome Acquisition, Capex, Management change, Results | Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.AI summaryCohance Lifesciences filed the outcome of its board meeting held 6 November 2026, approving unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. Standalone revenue from operations for the quarter ended 30 September 2026 was Rs 416.69 crore versus Rs 497.79 crore a year earlier; standalone net profit was Rs 13.27 crore versus Rs 94.29 crore. Consolidated revenue from operations for the quarter was Rs 476.65 crore versus Rs 555.57 crore a year earlier; consolidated net profit attributable to shareholders was Rs 15.22 crore versus Rs 74.08 crore. The board appointed Dr. Kuber Jagdale (DIN 12037580) as Additional Director, designated Chief Technical Officer & Executive Director, for five years from 7 November 2026 to 6 November 2031, subject to shareholder approval. The board approved a proposed 26% equity investment in a solar power SPV under incorporation, for captive consumption at the company's plant operations. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Aug 2026 | credit rating Rating, Results | Cohance Lifesciences Limited has informed the Exchange about Credit Rating- OthersAI summaryCohance Lifesciences Limited filed intimation that CRISIL Ratings Limited, by letter dated 12 August 2026 and at the company's request, withdrew credit ratings on certain lower-limit bank facilities. CRISIL migrated ratings on the bank loan facilities of Rs 72.5 crore to 'Crisil BB/Stable/Crisil A4+ Issuer not cooperating' from 'Crisil BB/Positive/Crisil A1+' and then withdrew them, citing inadequate information and lack of management cooperation. The company stated the withdrawn facilities are covered by India Ratings and Research ratings on its higher-limit facilities, which remain valid and in force. The company stated the withdrawal has no impact on its existing credit facilities or borrowing arrangements. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Aug 2026 | transcript Acquisition, Capex, Guidance, Legal, Management change, Results | Cohance Lifesciences Limited has informed the Exchange about TranscriptAI summaryTranscript of Cohance Lifesciences' Q1 FY27 earnings conference call held on 05 August 2026, filed under Regulation 30. Management said Q1 FY27 was the company's lowest quarter ever, with consolidated revenue from operations of INR4,223 million (down 23% year-on-year) and adjusted EBITDA of INR92 million (2.2% margin); management expects sequential improvement in Q2 FY27 and year-on-year growth from the second half. Management said Pharma CDMO revenue declined 38.7% year-on-year due to shipment phasing, and Specialty Chemicals declined 34.7% year-on-year; Sapala revenue grew 2.5x to INR274 million while NJ Bio reported revenue of INR350 million and an adjusted EBITDA loss of INR328 million. Management said consolidated capex was about INR598 million and consolidated net cash was about INR2,512 million as of 30 June 2026. Management said Himanshu Agarwal (CFO) will remain until 13 September 2026 and a succession process is under way; Dr. P.Y. Reddy will lead the combined nucleic acid business through FY30 and a path to full ownership of Sapala by FY30 was agreed. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Aug 2026 | presentation Capex, Guidance, Results | Cohance Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryCohance Lifesciences filed its investor presentation on unaudited results for the quarter ended 30 June 2026 (Q1 FY27). Q1 FY27 revenue from operations was INR 4,223 Mn, down 23.1% YoY; adjusted EBITDA was INR 92 Mn (2.2% margin) versus INR 1,341 Mn a year earlier; adjusted loss after tax was INR (430) Mn. Reported PAT was INR (452) Mn; free cash flow was INR 1,063 Mn and cash on books INR 4,589 Mn; capex was INR 598 Mn. Management said Q1 was weak on shipment and order phasing, unfavourable product mix, negative operating leverage and NJ Bio subsidiary consolidation. Management expects sequential improvement from Q2 FY27, growth to return in H2 FY27, and EBITDA improvement weighted towards the second half. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Aug 2026 | board outcome Acquisition, Legal, Results | Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.AI summaryCohance Lifesciences reported unaudited standalone and consolidated results for the quarter ended 30 June 2026, approved by the board on 5 August 2026. Consolidated revenue from operations for the quarter was Rs 422.26 crores, against Rs 549.31 crores a year earlier; consolidated net loss after tax was Rs 45.19 crores, against a profit of Rs 46.40 crores a year earlier. Standalone revenue from operations for the quarter was Rs 359.89 crores, with a standalone net profit of Rs 1.41 crores. The board also approved a reorganisation at subsidiary Sapala Organics Private Limited, including amendment agreements with its selling shareholders, and convened the 8th AGM for 17 September 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 20 Jul 2026 | results Legal, Results | The Exchange had sought clarification from Cohance Lifesciences Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the CAI summaryCohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) wrote to NSE on 17 July 2026 responding to NSE's email of 10 July 2026. The NSE email sought clarification on financial results filed with the Outcome of Board Meeting dated 12 November 2025. The company said it had clarified the Non-Machine Readable Form of the results in an earlier communication dated 2 July 2026. The company also submitted revised financial results XBRL on 17 July 2026 and asked NSE to close the matter. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 15 May 2026 | transcript Capex, Guidance, Management change, Results | Cohance Lifesciences Limited has informed the Exchange about TranscriptAI summaryCohance Lifesciences filed the transcript of its Q4 and FY26 earnings conference call held on May 12, 2026. Himanshu Agarwal (CFO) said FY26 revenue was INR22.68 billion, down about 13% year-on-year; adjusted EBITDA was INR4.77 billion, a 21% margin; Q4 and FY26 were in line with prior guidance. Management said Q1 FY27 would be the low point for revenue and EBITDA, with Q2 expected to be stable and growth returning in H2 FY27; Q1 gross margin to be hit by about 100 to 150 bps from Middle East-related logistics and input cost inflation. Management expects FY27 capex of nearly INR3 billion, against INR2.15 billion in FY26. Yann D'Herve (CEO Pharma CDMO) said Pharma CDMO revenue was INR8.89 billion in FY26, with underlying growth of early single digits after destocking impact; API Plus revenue was INR10.88 billion, down 8%. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 May 2026 | presentation Capex, Guidance, Results | Cohance Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryCohance Lifesciences filed an investor presentation on its audited results for the quarter and year ended March 31, 2026. FY26 total revenue was INR 22.7 Bn, down 13.0% YoY; Adjusted EBITDA was INR 4.8 Bn (21.0% margin) and Adjusted PAT was INR 1.8 Bn (8.1% margin). Management said FY26 was a transition year affected by de-stocking in two large Pharma CDMO products, API+ segment decline of 8.0% YoY, and Specialty Chemicals decline of 2.1% YoY. Management said Q1 FY27 is likely to be the low point for revenue and EBITDA, with growth returning from 2H FY27. FY26 free cash flow was INR 1.73 Bn and capex was INR 2.15 Bn. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 May 2026 | board outcome Legal, Management change, Results | Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.AI summaryCohance Lifesciences' board, at its meeting on May 12, 2026, approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with the investor presentation and press release. Standalone revenue from operations for FY2026 was Rs 2,030.50 crore versus Rs 2,504.43 crore in FY2025; standalone net profit was Rs 122.77 crore for Q4 FY2026 and Rs 228.71 crore... [see note] Consolidated revenue from operations for FY2026 was Rs 2,268.55 crore versus Rs 2,608.50 crore in FY2025; consolidated net profit after tax was Rs 150.12 crore for FY2026 versus Rs 484.24 crore in FY2025. The board also revised the authorised Key Managerial Personnel for determining materiality of events under Regulation 30 of SEBI Listing Regulations, effective May 12, 2026, naming Umang Vohra (Chairman), Himanshu Agarwal (Whole-time Director and CFO) and Sisir K. Mishra (Company Secretary and Compliance Officer). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Apr 2026 | board outcome Acquisition, Management change | Cohance Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on April 27, 2026.AI summaryBoard of Cohance Lifesciences Limited, at its meeting on April 27, 2026, noted the resignation of Mr. Vivek Sharma as Executive Chairman and director, effective close of business April 30, 2026; he will continue as Special Advisor for the next 9 months. Board approved appointment of Mr. Umang Vohra (DIN: 02296740) as Additional Director, designated Chairman, effective May 1, 2026 for a term to April 30, 2031, and as Group Chief Executive Officer effective May 20, 2026, subject to shareholder and regulatory approvals. Board approved adoption of the Cohance Lifesciences Limited Employee Stock Option Plan, 2026, under the SEBI Share Based Employee Benefits and Sweat Equity Regulations, 2021, subject to shareholder approval. Board approved a postal ballot notice seeking shareholder approval for the Vohra appointment, the ESOP plan and related matters. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 16 Feb 2026 | transcript Guidance, Legal, Results | Cohance Lifesciences Limited has informed the Exchange about TranscriptAI summaryCohance Lifesciences filed the transcript of its earnings conference call held February 12, 2026, for the quarter and nine months ended December 31, 2025. Executive Chairman Vivek Sharma said recent performance was below expectations and revised the FY26 revenue outlook to an early-to-mid double-digit decline, attributing it to timing and product-mix factors, and said FY27 is expected to be a year of growth. Management said Pharma CDMO revenue in Q3 declined 27% year-on-year, or grew 7% after adjusting for destocking, and that API Plus revenue for nine months fell 8% to INR8.15 billion. Management said Specialty Chemicals revenue for nine months rose 32% year-on-year to INR1.9 billion. CFO Himanshu Agarwal said nine-month revenue declined 6.7% to INR1,650 crore and adjusted EBITDA declined 43% to INR348 crore, with gross margin up 204 basis points to 72.8%. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Feb 2026 | presentation Capex, Guidance, Results | Cohance Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryCohance Lifesciences filed its investor presentation on unaudited results for the quarter and nine months ended December 31, 2025. Management said FY26 is a transition and bottoming phase, and FY26 revenue guidance is revised to an early-to-mid double-digit decline; management expects a return to revenue growth in FY27. 9MFY26 total revenue was INR 16.5 bn (down 6.7% YoY), adjusted EBITDA INR 3.5 bn with 21.1% margin, and adjusted PAT INR 1.5 bn (9.2% margin). Management attributed the Nacharam facility warning letter to about INR 55 crore of shipment deferrals, and said Pharma CDMO revenue fell 12.7% YoY while Specialty Chemicals grew 31.6% YoY. Free cash flow was INR 1.75 bn in 9MFY26 and cash on books was INR 4.32 bn; capex deployed was INR 1.61 bn. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Feb 2026 | board outcome Legal, Results | Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.AI summaryCohance Lifesciences Limited (formerly Suven Pharmaceuticals) filed the outcome of its board meeting held on February 12, 2026, approving unaudited standalone and consolidated Ind AS results for the quarter and nine months ended December 31, 2025. Consolidated revenue from operations for the quarter ended December 31, 2025 was Rs 544.55 crore, and consolidated net profit attributable to shareholders was Rs 36.77 crore, with basic EPS of Rs 0.96 (not annualised). Standalone revenue from operations for the quarter was Rs 481.58 crore, and standalone net profit was Rs 47.29 crore, with basic EPS of Rs 1.24 (not annualised). Exceptional items for the quarter of Rs 4.86 crore relate to the impact of new labour codes, and the note also mentions a one-time restructuring expense of Rs 8.10 crore linked to the merger. The board also approved revisions to the authorised KMPs for materiality determination under Regulation 30(5), effective February 12, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 Jan 2026 | results | The Exchange has sought clarification from Cohance Lifesciences Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the C | |
| 03 Dec 2025 | credit rating Rating | Cohance Lifesciences Limited has informed the Exchange about Credit RatingAI summaryCohance Lifesciences Limited (formerly Suven Pharmaceuticals) filed a Regulation 30 disclosure dated December 3, 2025 on a credit rating. India Ratings & Research assigned a rating of IND AA/Stable/IND A1+ to the Company's bank loan facilities, size of issue INR 6,850 million, rating action "Assigned". The annexure lists the facility breakup across banks, including term loans from Citibank N.A. (INR 343 million) and Axis Bank (INR 833 million), and fund-based and non-fund-based working capital limits from several banks. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 17 Nov 2025 | transcript Guidance, Results | Cohance Lifesciences Limited has informed the Exchange about TranscriptAI summaryCohance Lifesciences filed the transcript of its Q2 and H1 FY26 earnings conference call held on November 12, 2025. Management said Q2 revenue was INR5,556 million, down 8% year-on-year due to deferred shipments and restocking, and up 14% adjusted for restocking; Q2 adjusted EBITDA margin was 23.2%. H1 FY26 revenue was INR11,049 million, up 1% year-on-year (20% growth adjusted for restocking); H1 adjusted EBITDA was INR2,630 million at a 23.8% margin and adjusted PAT was INR1,302 million. Management revised FY26 revenue guidance to broadly flattish versus FY25, expects H2 to be stronger than H1, and expects growth to return in FY27, with more informed guidance by Q3 or Q4 FY26. Management maintained its mid-term target of US$1 billion revenue with a mid-30s margin. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Nov 2025 | presentation Guidance, Results | Cohance Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryCohance Lifesciences filed its investor presentation on unaudited results for the quarter and half year ended September 30, 2025 (Q2FY2026 / 1HFY26). CDMO revenue declined 4% YoY in 1HFY26, mainly due to destocking in two commercial molecules, delays in some Phase 2-3 reloads and biotech funding impact at NJ Bio. API+ declined 4% YoY, mainly due to the Nacharam plant shutdown. Specialty Chemicals (Agro + Performance Chem) grew 84% YoY. Management revised FY26 outlook to flattish revenue growth YoY, expecting 2H performance to be better than 1H. Management said it expects growth to return in FY27 and will provide a more informed guidance by Q3/Q4 FY26. Management maintained its longer-term target of US$1bn (INR 85bn) revenue with mid-30s EBITDA margins. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Nov 2025 | board outcome Guidance, Results | Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.AI summaryBoard of Cohance Lifesciences Limited (formerly Suven Pharmaceuticals) approved unaudited standalone and consolidated Ind AS results for the quarter and half year ended September 30, 2025, at a meeting held November 12, 2025 (5:30 pm to 6:10 pm IST). Q2FY26 revenue was ₹5,556 million, down 8% year-on-year, which management attributed to deferred shipments, destocking and project timing (NJ Bio); adjusted for destocking, growth was 14% YoY. Q2FY26 adjusted EBITDA was ₹1,289 million, a 23.2% margin; gross margin was 74.6% versus about 71.3% a year earlier. 1HFY26 revenue was ₹11,049 million, up 1.2% year-on-year (20% growth adjusted for destocking); adjusted EBITDA was ₹2,630 million, a 23.8% margin. Management said it expects 2H performance to be better than 1H and remains on track for a USD 1 billion (₹85 billion) revenue target by 2030 with mid-30s EBITDA margins. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 01 Nov 2025 | transcript Guidance, Legal, Management change | Cohance Lifesciences Limited has informed the Exchange about TranscriptAI summaryCohance Lifesciences filed the transcript of its update conference call held on October 28, 2025, on the change in directors. Executive Chairman Vivek Sharma said Managing Director Dr. Prasada Raju stepped down effective immediately, citing personal priorities, and will remain associated for an orderly transition ending this fiscal. Management said the board approved a revised structure in which three business unit leaders report directly to the Executive Chairman, a platform COO is to join shortly, and CFO Himanshu Agarwal will join the board as director. Management said the strategy is unchanged and the US$1 billion business vision by 2030 remains; it cited four completed CDMO customer orders and a confirmed Phase 3 order from a large Japanese customer. Management said the Nacharam FTF unit is in remediation after an OAI classification, and that this business is less than 1% of overall EBITDA; management did not discuss quarterly financial numbers, citing the silent period. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Aug 2025 | credit rating Rating | Cohance Lifesciences Limited has informed the Exchange about Credit RatingAI summaryCRISIL upgraded the long-term bank loan facilities rating of Cohance Lifesciences Limited to 'CRISIL AA-/Positive' from 'CRISIL A+', removing it from 'Rating Watch with Positive Implications'; the short-term rating of 'CRISIL A1+' was reaffirmed. Total bank loan facilities rated are Rs 72.5 crore, per the rating letter dated August 26, 2025. CRISIL cited the amalgamation of Cohance Lifesciences with erstwhile Suven Pharmaceuticals, effective May 1, 2025, and the acquisitions of NJ Bio Inc and Sapala Organics, as strengthening the business and financial risk profiles. The outlook assigned is Positive; upward factors include revenue of around Rs 3,000 crore with margins above 30%. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 Aug 2025 | transcript Capex, Guidance, Management change, Results | Cohance Lifesciences Limited has informed the Exchange about TranscriptAI summaryCohance Lifesciences filed the transcript of its Q1 FY'26 earnings conference call (quarter ended June 30, 2025), held after the August 13, 2025 board meeting. Management said revenue grew 13% year-on-year in Q1 FY'26; excluding inventory de-stocking in Pharma CDMO, revenue growth exceeded 25%, and the Pharma CDMO segment grew 1% reported, or over 30% excluding de-stocking. Management reiterated FY'26 guidance and its long-term target of USD 1 billion (INR 85 billion) revenue by 2030, with medium-term mid-30s EBITDA margins intact. Management said Q1 capex was INR 559 million and free cash flow was INR 2.3 billion, with cash of INR 4.4 billion at quarter end. Management announced a USD 10 million investment to expand a cGMP bioconjugation suite at the Princeton facility and an INR 230 million cGMP oligonucleotide building block facility at Nacharam, expected to be fully operational by end of CY 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Aug 2025 | presentation Guidance, Management change, Results | Cohance Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryCohance Lifesciences filed an investor presentation on its unaudited financial results for the quarter ended June 30, 2025 (Q1FY26). Management said Q1 revenue grew 13% YoY with gross margin expansion; EBITDA margins reflect planned investments in talent and business development; adjusted for inventory de-stocking, overall business grew ahead of 25% YoY. Pharma CDMO revenue grew 1% YoY (about +30% adjusted for de-stocking); API+ revenue grew about 19% YoY; Specialty Chemicals revenue grew 28% YoY. Management reiterated its long-term vision of USD 1 billion (INR 85 billion) revenue by 2030 with mid-30s EBITDA margins, and said performance is best evaluated on a full-year basis given the lumpy nature of the industry. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Aug 2025 | board outcome Legal, Results | Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summaryCohance Lifesciences (formerly Suven Pharmaceuticals) filed its board meeting outcome on August 13, 2025, approving unaudited standalone and consolidated Ind AS results for the quarter ended June 30, 2025. Standalone revenue from operations for the quarter ended June 30, 2025 was Rs 483.5 crore (as printed "4B3.5B"), with standalone net profit of Rs 52.57 crore. Consolidated revenue from operations for the quarter was Rs 549.31 crore, with consolidated net profit attributable to shareholders of Rs 48.88 crore. The board revised the list of authorised Key Managerial Personnel for materiality determination under Regulation 30(5), effective August 13, 2025, and amended the materiality policy accordingly; the authorised persons are Vivek Sharma, V Prasada Raju, Himanshu Agarwal and Kundan Kumar Jha. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 02 Jun 2025 | transcript Acquisition, Capex, Guidance, Results | Cohance Lifesciences Limited has informed the Exchange about TranscriptAI summaryCohance Lifesciences filed the transcript of its Q4 and FY25 earnings conference call held on May 28, 2025, following the Board meeting of the same date. Management said FY25 revenue grew 9% year-on-year to a $335 million platform, with full-year EBITDA margin of 34%; Q4 FY25 revenue grew 20% year-on-year with adjusted EBITDA margin of 31.3%. Management guided to double-digit revenue growth in FY26 and EBITDA margins in the low 30s for FY26, with a mid-term target in the mid-30s at scale; Q1 FY26 is expected to be muted. Management said capex totalled $3.1 billion (as stated in the call), free cash flow was Rs. 3.6 billion, and cash and bank balance was Rs. 2.9 billion. Management reiterated a vision of $1 billion global revenue by 2030 and said the Pharma CDMO, Specialty Chemicals and API+ segments are expected to grow double digits in FY26. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2025 | credit rating Acquisition, Legal, Rating | Cohance Lifesciences Limited has informed the Exchange about Credit RatingAI summaryCRISIL has continued its long-term bank facility rating of Cohance Lifesciences Limited at CRISIL A+/Watch Positive (Rating Watch with Positive Implications) and reaffirmed the short-term rating at CRISIL A1+, covering bank loan facilities of Rs.72.5 crore. The watch was placed on Feb 29, 2024, after the announced amalgamation of CLL with Suven Pharmaceuticals Ltd; the merger took effect from May 1, 2025 and the combined entity was renamed CLL. CRISIL noted the acquisition of 56% of NJ Bio Inc on Dec 20, 2024 for Rs. 547.96 crore, paid from cash reserves; it is still evaluating the impact of the acquisitions and amalgamation and will remove the ratings from watch once the assessment is complete. CRISIL cited FY2024 operating income of Rs. 1051.35 crore and PAT of Rs. 300.28 crore, and expects net cash accruals above Rs. 300 crore in fiscal 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 May 2025 | presentation Acquisition, Legal, Results | Cohance Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryCohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) filed its investor presentation and press release on audited results for the quarter and year ended March 31, 2025. The Ministry of Corporate Affairs approved the name change from Suven Pharmaceuticals Limited to Cohance Lifesciences Limited, effective May 7, 2025; new name and ticker effective on both exchanges from May 19, 2025. A merger is stated as effective from May 1, 2025; market capitalization is stated as US$4.95 bn (INR 425 bn, CMP INR 1112). Management describes the company as a specialized, technology-driven global CDMO with 16 patented commercial small molecules, 14 plants, 3500 KL capacity and a Phase III pipeline of 9 molecules. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 May 2025 | board outcome Results | Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.AI summaryCohance Lifesciences Limited (formerly Suven Pharmaceuticals) filed the outcome of its May 28, 2025 board meeting, which approved audited standalone and consolidated Ind AS results for the quarter and year ended March 31, 2025. Standalone revenue from operations for FY2025 was Rs 1,093.51 crores and net profit was Rs 271.71 crores, versus Rs 1,051.35 crores and Rs 296.47 crores in FY2024. Consolidated revenue from operations for FY2025 was Rs 1,197.58 crores and net profit was Rs 264.77 crores, versus Rs 1,051.35 crores and Rs 300.28 crores in FY2024. Consolidated net profit for the March 2025 quarter was Rs 38.73 crores, against Rs 83.29 crores in the December 2024 quarter and Rs 53.37 crores in the March 2024 quarter. Audit reports carry unmodified opinions, and a press release and investor presentation were annexed. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Feb 2025 | credit rating Acquisition, Rating | Suven Pharmaceuticals Limited has informed the Exchange about Credit RatingAI summarySuven Pharmaceuticals Limited filed a credit rating disclosure under Regulation 30, dated February 28, 2025, citing a CRISIL letter received the same day. CRISIL continued the long-term bank facilities rating at CRISIL A+/Watch Positive (Rating Watch with Positive Implications) and reaffirmed the short-term rating at CRISIL A1+; total bank loan facilities rated are Rs. 72.5 crore. The watch relates to the proposed amalgamation of Cohance Lifesciences Ltd into Suven Pharmaceuticals, which has shareholder approval (99.99% in favour) and is awaiting final NCLT hearing. The rationale also notes the acquisition of 56% of NJ Bio Inc on December 20, 2024 for Rs. 547.96 crore, paid from cash reserves. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 Feb 2025 | transcript Acquisition, Capex, Guidance, Legal, Results | Suven Pharmaceuticals Limited has informed the Exchange about TranscriptAI summarySuven Pharmaceuticals filed the transcript of its Q3 FY'25 and nine-month earnings conference call held February 12, 2025 (quarter and nine months ended December 31, 2024). Management said Q3 revenue grew 40% year-on-year on a pro forma combined basis, with adjusted EBITDA margin at 38.7%; nine-month revenue grew 5% year-on-year with adjusted EBITDA margin at 34.8%. Management said 9-month capex was Rs. 2.3 billion and cash generation was Rs. 3.2 billion. Management reaffirmed FY'25 guidance of year-on-year growth on a pro forma combined basis and expects accelerated growth in FY'26. Management said the Cohance merger received 99.99% shareholder approval, the final NCLT meeting was scheduled for February 18, and the merger is expected to be effective within 2 to 4 months subject to regulatory approvals. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Feb 2025 | results Acquisition, Legal, Results | Integrated filing - Financials for Q3FY25AI summarySuven Pharmaceuticals Limited filed unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, with Limited Review Report from statutory auditors. Standalone revenue from operations for the quarter ended 31-Dec-24 was Rs 275.39 crores, against Rs 236.06 crores for the quarter ended 30-Sep-24; standalone net profit was Rs 86.26 crores (Rs 76.26 crores in the quarter ended 30-Sep-24). Consolidated revenue from operations for the quarter ended 31-Dec-24 was Rs 307.15 crores; consolidated net profit attributable to shareholders was Rs 82.88 crores (quarter ended 30-Sep-24: Rs 82.21 crores). The company acquired 56% of NJ Bio Inc on 20 December 2024 for Rs 547.96 crores, and earlier acquired 51% of Sapala Organics on 12 July 2024 for Rs 258.00 crores. The Scheme of Amalgamation of Casper Pharma Private Limited has been sanctioned by NCLT with an effective date of 1 January 2025; the Cohance Life Sciences amalgamation remains subject to approvals. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Feb 2025 | presentation Acquisition, Capex, Guidance, Results | Suven Pharmaceuticals Limited has informed the Exchange about Investor PresentationAI summaryInvestor presentation for Q3 and 9MFY25 (proforma basis, subject to proposed amalgamation of Cohance Lifesciences with Suven Pharmaceuticals), per management. Q3FY25 proforma revenue from operations was INR 6,764 mn, up 40% YoY; adjusted EBITDA was INR 2,620 mn (38.7% margin) and adjusted PAT was INR 1,681 mn (24.8% margin). 9MFY25 proforma revenue from operations was INR 17,691 mn, up 4.7% YoY; adjusted EBITDA was INR 6,149 mn (34.8% margin); 9M capex spent was INR 2.31 bn. Management said the Pharma CDMO segment grew 101% YoY in Q3, SpeChem CDMO recovered sequentially after bottoming in Q2, and FY25 is expected to grow YoY on a combined basis with acceleration in FY26. Shareholders approved the merger (99.99% in favour); final NCLT hearing is on February 18, with the merger expected to be effective in Q1FY26, subject to regulatory approvals. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Feb 2025 | results Acquisition, Legal, Results | Suven Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.AI summarySuven Pharmaceuticals Limited filed its unaudited standalone and consolidated Ind AS financial results for the quarter and nine months ended 31 December 2024, approved by the Board on 12 February 2025. Consolidated revenue from operations for the quarter ended 31 December 2024 was Rs 307.15 crore, against Rs 257.72 crore in the quarter ended 30 September 2024 and Rs 219.82 crore in the quarter ended 31 December 2023. Consolidated net profit attributable to shareholders for the quarter ended 31 December 2024 was Rs 82.88 crore, against Rs 82.21 crore in the previous quarter and Rs 46.75 crore a year earlier. Standalone revenue from operations for the quarter ended 31 December 2024 was Rs 275.39 crore; standalone net profit was Rs 86.26 crore. The company acquired 56% of NJ Bio Inc on 20 December 2024 for Rs 547.96 crore and 51% of Sapala Organics Private Limited on 12 July 2024 for Rs 258.00 crore; the scheme of amalgamation of Cohance Life Sciences into the company remains subject to approvals, including from NCLT. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Dec 2024 | transcript Acquisition, Capex | Suven Pharmaceuticals Limited has informed the Exchange about TranscriptAI summarySuven Pharmaceuticals filed the transcript of its investor/analyst conference call held on December 09, 2024, on its intent to acquire a majority stake in NJ Bio, Inc., a US (Princeton, New Jersey) ADC-focused CRDMO. Management said Suven is acquiring a 56% stake at a pre-money equity value of approximately US $100 million, valuing it at low to mid-teens EV/EBITDA for CY25, with total investment of US $64.4 million (US $49.4 million secondary purchase and US $15 million primary infusion). Management said NJ Bio is expected to achieve revenue of US $32 million for the 12 months ending December 2024, and the transaction is expected to close before the end of December, subject to regulatory approvals. Management said Suven's cash reserve was 6.5 billion as of September 2024 (currency unit as printed) and that margins are expected to progressively approach 20% plus. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Dec 2024 | presentation Acquisition, Capex, Guidance | Suven Pharmaceuticals Limited has informed the Exchange about Investor PresentationAI summarySuven Pharmaceuticals filed a press release and investor presentation on its acquisition of a controlling stake in NJ Bio Inc., a Princeton, US-based ADC/XDC-focused CRDMO. Suven will acquire a 56% stake at a US$100mn pre-money valuation, investing US$64.4mn in total, including US$49.4mn to buy out existing minority shareholders and US$15mn as primary equity infusion mainly for capex (GMP expansion at the Princeton facility). A call/put option arrangement to acquire the balance stake after 5 years was disclosed. NJ Bio is expected to record revenues of about US$32mn in CY24, and the transaction is expected to close before the end of December 2024. Management will hold a conference call on December 9, 2024 at 11:30 am IST. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Dec 2024 | presentation Acquisition, Capex | Suven Pharmaceuticals Limited has informed the Exchange regarding a press release and investor presentation dated December 07, 2024, titled "Acquisition".AI summarySuven Pharmaceuticals filed a press release and investor presentation on its acquisition of a controlling stake in NJ Bio Inc., a Princeton, US-based ADC/XDC-focused CRDMO. Suven will acquire a 56% stake at a US$100mn pre-money valuation, investing US$64.4mn, including US$49.4mn to buy out existing minority shareholders and US$15mn as primary equity for growth initiatives such as GMP expansion at the Princeton facility. NJ Bio expects revenues of about US$32mn in CY24, and the transaction is expected to close before the end of December 2024. A call/put option arrangement exists to acquire the balance stake after 5 years. Executive Chairman Vivek Sharma said the transaction is in line with Suven's vision of being a technology-led CDMO offering end-to-end solutions in emerging modalities like ADCs. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Dec 2024 | board outcome Acquisition | Suven Pharmaceuticals Limited has informed the Exchange regarding acquisition.AI summarySuven Pharmaceuticals Limited executed definitive agreements on December 7, 2024 to acquire a 56% equity stake in NJ Bio, Inc., a Princeton, New Jersey-based antibody-drug conjugate (ADC) and XDC focused CRDMO. The deal is by a mix of secondary acquisition and primary infusion at a pre-money equity value of USD 100 million, with total investment of USD 64.4 million, including USD 15 million primary equity infusion. The target's turnover was USD 6.5 million in CY2021, USD 17.7 million in CY2022 and USD 21.6 million in CY2023. The company has a call option, and the remaining shareholders a put option, after 5 years to take the stake to 100%. The company expects to complete the transaction before end of December 2024, subject to customary closing conditions; consideration is entirely cash. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Nov 2024 | credit rating Acquisition, Rating | Suven Pharmaceuticals Limited has informed the Exchange about Credit RatingAI summarySuven Pharmaceuticals Limited filed a credit rating intimation under Regulation 30 for the bank facilities rated by CRISIL, dated November 29, 2024. CRISIL continued the long-term rating at CRISIL A+/Watch Positive (Rating Watch with Positive Implications) and reaffirmed the short-term rating at CRISIL A1+. The watch relates to the proposed scheme of amalgamation of Cohance Lifesciences Ltd into and with Suven Pharmaceuticals; CRISIL said it will take a final rating action once there is more clarity on the transaction. CRISIL cited operating income of Rs 1051.35 crore and profit after tax of Rs 300.28 crore for fiscal 2024, and net worth of around Rs 1978 crore as on September 30, 2024. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.